Oncoprint representing distribution of oncogenic and variants of uncertain significance (VUS) in ctDNA at baseline.
ENDOMETRIOID CARCINOMA
Cohort 1 includes patient identifications listed as NEC-2–27 (In four patients who had a long response to treatment (PFS > 6 months), ctDNA was collected at a second time point. The two patients from C1 (NEC11—grade 3 endometrioid carcinoma and NEC16—serous EC; Figs. 